Legend Biotech
LEGN
170 hedge funds and large institutions have $3.18B invested in Legend Biotech in 2022 Q4 according to their latest regulatory filings, with 28 funds opening new positions, 59 increasing their positions, 58 reducing their positions, and 17 closing their positions.
254% more call options, than puts
Call options by funds: $32.8M | Put options by funds: $9.27M
65% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 17
20% more capital invested
Capital invested by funds: $2.64B → $3.18B (+$540M)
7% more funds holding
Funds holding: 159 → 170 (+11)
2% more repeat investments, than reductions
Existing positions increased: 59 | Existing positions reduced: 58
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
1.06% less ownership
Funds ownership: 20.16% → 19.1% (-1.1%)
Top Buyers
Top Sellers
LEGN Hedge Fund Activity: Q4 2022 in Review
170 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Legend Biotech (LEGN) for Q4 2022, worth a combined $3.18B — up 20% from $2.64B a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new LEGN positions and 17 closed out — a net gain of 11 holders — while 59 added to existing stakes and 58 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $124M. The largest seller was Janus Henderson Group, cutting an estimated $90.9M.
- 170 institutional investors held Legend Biotech (LEGN) as of Q4 2022, up from 159 in Q3 2022.
- Funds reported $3.18B of Legend Biotech stock for Q4 2022, up 20% quarter-over-quarter.
- 28 funds opened new Legend Biotech positions in Q4 2022 and 17 closed out, a net change of +11 holders.
- The largest Legend Biotech buyer in Q4 2022 was Fidelity Investments, an estimated $124M added.
- The largest Legend Biotech seller in Q4 2022 was Janus Henderson Group, an estimated $90.9M sold.
Based on aggregated 13F filings for Q4 2022.